← All trials
NCT06934941
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 25, 2024
- Primary completion
- Oct 30, 2025
- Completion date
- Mar 30, 2026
- First posted
- Apr 18, 2025
- Last posted
- Apr 18, 2025
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NeuramedyLead sponsor
- Seoul National UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.